MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors

MeiraGTx adds an experienced biopharmaceutical investor to its board as it advances late-stage genetic medicine programs and in-house manufacturing platforms.

Rhea-AI Summary

MeiraGTx (MGTX) appointed veteran healthcare portfolio manager Alan M. Sebulsky to its Board of Directors, effective September 23, 2026.

Sebulsky has over 40 years of experience in public company investment, financial strategy and board leadership, including 14 years as Partner and Portfolio Manager at Adage Capital Management, where he led a diversified biopharmaceutical portfolio with over $2 billion in assets. He founded and now leads Apothecary Capital and currently serves on the board of Parabilis Medicines. MeiraGTx is a vertically integrated, clinical-stage genetic medicines company with four late-stage programs, extensive in-house GMP manufacturing capabilities and a riboswitch gene regulation platform.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LONDON and NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the appointment of Alan M. Sebulsky to its Board of Directors.

Mr. Sebulsky is a veteran healthcare portfolio manager and biopharmaceutical investment analyst with more than 40 years of experience in public company investment, financial strategy, portfolio evaluation and growth, and board leadership. Mr. Sebulsky most recently served as Partner and Portfolio Manager at Adage Capital Management for the past 14 years, where he led a team overseeing a diversified biopharmaceutical portfolio with over $2 billion in assets. Prior to this, he founded Apothecary Capital, an asset management firm focused on investments across the healthcare and biopharmaceutical sectors. He reestablished Apothecary in April 2026 and currently serves as the Managing Member.

Mr. Sebulsky currently serves on the Board of Directors of Parabilis Medicines, Inc. and previously served on the Boards of Directors and Audit Committees for both Jazz Pharmaceuticals and Arrow International, two publicly traded healthcare companies, and on the boards of three private healthcare companies in which Apothecary Capital invested. In these roles, he worked closely with company leadership to advance portfolio, commercial and business strategy.

Mr. Sebulsky holds an M.S. in finance and a B.B.A. in finance and economics from the University of Wisconsin–Madison.

“We are delighted to welcome Alan to our Board of Directors,” said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx. “I have known Alan for 25 years and I have always had the highest respect for him both professionally and personally. His decades of investing in and working with biopharmaceutical companies brings a valuable perspective to the board which is particularly important as we continue to transform MeiraGTx into a commercial company.”

Keith Harris, Chairman of the Board of Directors of MeiraGTx, added, “I am pleased that Alan is joining our board. He brings an extensive wealth of knowledge of our sector and public company experience. We look forward to his invaluable assistance in helping the further growth of our Company.”

About MeiraGTx

MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage genetic medicines company with a broad pipeline with four late-stage clinical programs. Each of these programs use local delivery of small doses resulting in disease modifying effects in both inherited and more common diseases, in the eye, radiation-induced xerostomia, and Parkinson’s disease. MeiraGTx uses its innovative technology in optimization of capsids, promoters and novel translational control elements to develop best in class, potent, safe viral vectors. MeiraGTx’s broad pipeline is supported by end-to-end in-house manufacturing. MeiraGTx has built the most comprehensive manufacturing capabilities in the industry, including two that are licensed for GMP viral vector production and a GMP QC facility with clinical and commercial licensure. In addition, MeiraGTx has developed a proprietary manufacturing platform process over 10 years based on more than 20 different viral vectors with leading yield and quality aspects and commercial readiness. Uniquely, MeiraGTx has developed a novel technology for in vivo delivery of any biologic therapeutic using oral small molecules. This transformative riboswitch gene regulation technology allows precise, dose-responsive control of gene expression by oral small molecules. MeiraGTx is focusing the riboswitch platform on the regulated in vivo delivery of metabolic peptides, including GLP-1, GIP, Glucagon, Amylin, PYY and Leptin, as well as cell therapy, CAR-T for liquid and solid tumors and autoimmune diseases, and additionally PNS targets addressing long term intractable pain. MeiraGTx has developed the technology to apply genetic medicine to common diseases, increasing efficacy, addressing novel targets, and expanding access in some of the largest disease areas where the unmet need remains high.

For more information, please visit www.meiragtx.com.

Contacts

Investors:
MeiraGTx
Investors@meiragtx.com

or

Media:
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is Alan M. Sebulsky and what relevant experience does he bring to MeiraGTx?

Alan M. Sebulsky is a healthcare portfolio manager and biopharmaceutical investment analyst with more than 40 years of experience in public company investment, financial strategy, portfolio evaluation and growth, and board leadership. He spent the past 14 years as Partner and Portfolio Manager at Adage Capital Management overseeing a diversified biopharmaceutical portfolio with over $2 billion in assets, founded and reestablished Apothecary Capital, and has served on boards and audit committees of multiple public and private healthcare companies.

What is the business focus of MeiraGTx?

MeiraGTx is a vertically integrated, clinical-stage genetic medicines company with a broad pipeline that includes four late-stage clinical programs targeting inherited and more common diseases in the eye, radiation-induced xerostomia and Parkinson’s disease. The company supports this pipeline with end-to-end in-house manufacturing, including two GMP-licensed viral vector facilities and a GMP QC facility, and has also developed a riboswitch gene regulation platform for in vivo delivery and control of biologic therapeutics using oral small molecules.